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Background: More than half of patients with colorectal cancer will develop metastatic disease either evident at the
time of initial diagnosis or during their course of disease. Besides multidisciplinary management further treatment
intensification is warranted to improve the still limited prognosis.
Methods/design: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with
R0-resectable colorectal liver metastases (PERIMAX) and with unresectable, metastatic colorectal cancer (CHARTA)
will be recruited. Patients previously untreated for metastatic disease with either synchronous or metachronous
metastases are randomly assigned in a 1:1 ratio to resection of colorectal liver metastases followed by postoperative
FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and
resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/− irinotecan for a maximum
of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab. The primary objective of
these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at
9 months in CHARTA. Secondary objectives include efficacy, safety and tolerability.
Discussion: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active
four-drug regimen in distinct treatment situations of metastatic CRC. Eligible patients are classified into resectable
liver metastases to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative
FOLFOX in the PERIMAX, or unresectable metastatic CRC to be randomized between FOLFOX and bevacizumab
with or without irinotecan, stratified for clinical groups according to disease and patients’ characteristics in the
CHARTA trial.
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Colorectal cancer (CRC) is the most frequently diag-
nosed cancer in Europe and one of the leading causes of
cancer death worldwide [1,2]. About 20-25% of patients
with CRC present with metastatic disease at time of
diagnosis, and further 20-25% of patients will develop
metastases after curative resection, of whom 20-30%
present with liver metastases only [3,4]. Upfront stratifi-
cation of patients with metastatic CRC (mCRC) into
clinical groups according to clinical presentation and
treatment aim by a multidisciplinary team is of utmost
importance for the prognosis of the individual patient
[5]. Clinical groups based on current guidelines and
recommendations are displayed in Table 1 [6,7]. Recent
retrospective series demonstrated profound improve-
ments in outcome of patients with colorectal cancer over
the last 20 years due to advancements in chemotherapy
and dramatic increase in patients undergoing liver resec-
tion for either primarily or secondarily resectable colo-
rectal liver metastases (CLM), resulting in an overall
survival (OS) comparable to that of stage III (UICC)
colon cancer [8,9].
Management of R0 resectable liver metastases
Resection of CLM is a potentially curative treatment,
and reported 5-year survival rates are about 40% [10,11].
Further follow up after resection of liver metastases from
colorectal cancer demonstrated long-term survival and
finally cure for every fifth patient even in the presence
of poor prognostic factors [12-15]. However, with the
majority of patients relapsing after liver resection, either
intrahepatic (about 70%), extrahepatic (about 50%), or
both, further research is urgently warranted [16].
Selection of patients for a potentially curative approach
The selection of patients for hepatic surgery is a contro-
versial issue. The most commonly used scoring system for
prediction of OS described by Fong and colleagues incor-
porates five risk factors: node-positive primary, disease-
free interval <12 months, >1 lesion, size >5 cm, and CEA
>200 ng/m. Patients with 5 risk factors had a 5 year OS
rate (5-yOSR) of 14% with a median of 22 months com-
pared to a 5-yOSR of 44% and a median of 51 months inTable 1 Clinical groups for first-line treatment
stratification
group clinical presentation
0 clearly R0-resectable liver and/or lung metastases
1 unresectable liver and/or lung metastasis potentially
resectable after downsizing, comorbidities allowing surgery
2 multiple metastasis, rapid progression, risk of rapid
deterioration, unlikely to become resectable
3 never resectable and no symptoms or risk of deteriorationcase of one risk factor [14]. Recently, the international
liver metastases survey, including data of about 4500
patients with preoperatively treated CLM, confirmed the
poor prognosis of patients with lymph node positive pri-
mary, abnormal CEA levels, and a high number of CLM,
although cut off value was >3 [15].
Whereas the estimation of survival is broadly accepted,
criteria for resectability are far from being well and
uniformly defined [17-21]. Generally, a post-resection
remnant liver of less than 30%, unfavourable location
of metastases, co-morbidities excluding major surgery,
aggressive tumour biology, and/or presence of extrahe-
patic disease are regarded as limitations for liver surgery.
However, liver resection should have the potential for
complete macroscopic resection in curative intent [21].
Perioperative treatment for resectable CLM
The EORTC 40983 trial accrued 364 patients to be
randomized to two treatment arms: surgery alone or
chemotherapy with 5-FU/LV and oxaliplatin (FOLFOX4
regimen), administered 3 months pre- and postopera-
tively. [22]. Patients had to be technically resectable
(assessed by CT scan) with a maximum of 4 CLM and
no prior treatment with chemotherapy. Despite favour-
able patients’ characteristics, with more than 50% bear-
ing only a single CLM and about 80% with up to 2,
respectively, and performance of surgery in “high qual-
ity” institutions, the reported 3 year progression free
survival rates (3-yPFSR) were relatively poor. In the
group of patients (n=171) receiving the planned chemo-
therapy and resection of CLM 3-yPFSR significantly
increased from 33.2% (surgery alone) to 42.4% (HR 0.73,
95% CI 0.55 to 0.97). However, in the “intent to treat
analyses”, the difference was not statistically signifi-
cant due to ineligibility of 6% of patients (HR 0.79,
95% CI 0.62 to 1.02). No unusual toxicities occurred
in the chemotherapy arm, and about 80% of patients
completed the preoperative part. After resection, 76% of
patients received postoperative treatment with the ma-
jority (52%; n=80) completing all 6 cycles.
Results of two single arm phase II trials using capecita-
bine, oxaliplatin and bevacizumab as neoadjuvant treat-
ment in about 100 patients with CLM either clearly R0
resectable or unlikely R0 resectable with poor prognosis
demonstrated feasibility of this regimen with an overall
response rate (ORR) of 73-78% and a conversion rate of
40% (12 of 30) in the unlikely resectable group [23,24].
Postoperative systemic treatment
Two randomized phase III trials have compared adju-
vant systemic chemotherapy with 5FU/LV after resection
of CLM to surgery alone, but both were closed prema-
turely due to slow accrual. By the time of closure, a
small but statistically significant improvement in disease
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with a 5-year DFS rate of 26.7 vs. 33.5% (p=0.028),
favouring the group with adjuvant treatment [25]. The
ENG (EORTC/NCI-CTG/GIVIO) trial, still not fully
published, showed a non-significant trend towards a pro-
longation of DFS (median 39 vs. 20 months; p=0.35) and
an increase in overall survival (median 53 vs. 43 months;
p = 0.39) [26]. The combined analysis of both trials
(n=278 patients) showed a non-significant prolongation
of DFS from 18.8 to 27.9 months (p = 0.058) and OS
from 47.3 to 62.2 months (p=0.095) [27]. Both trials were
using a (non-contemporary) 5-FU bolus regimen.
Intensification of postoperative treatment by 5-FU/LV
plus irinotecan in a prematurely stopped, randomized
phase III trial revealed no additional benefit com-
pared to 5-FU/LV alone in terms of DFS (21.6 vs.
24.7 months, p=0.47) and OS (3-year rate of 71.6 vs.
72.7%, p=0.69) [28].
The Dutch HEPATICA trial, prematurely stopped after
74 randomized patients, indicated that postoperative
treatment with capecitabine and oxaliplatin for 6 months
and bevacizumab for 12 months might be beneficial with
a trend in DFS rate at 2 years of 50 vs. 72% (p=0.074),
although this trend needs to be carefully interpreted in
regard of the known only transient benefit achieved
with prolonged bevacizumab in stage II/III colon can-
cer [29-31].
First line treatment for mCRC
Several first-line treatment options are currently available
incorporating fluoropyrimidines, irinotecan, oxaliplatin,
bevacizumab and EGFR antibodies (e.g. cetuximab and
panitumumab) for KRAS wildtype patients [32-37].
Bevacizumab based first line treatment for mCRC
A variety of trials and registry analyses evaluated the effi-
cacy of bevacizumab-containing first-line regimens. The
addition of bevacizumab to 5FU bolus and irinotecan
regimen (IFL) significantly increased ORR and pro-
longed OS and PFS [38]. The NO16966 study was ini-
tially designed to prove non-inferiority of the XELOX
regimen compared with FOLFOX-4, but the addition of
bevacizumab in a 2x2 factorial design was amended after
the above-mentioned results. Although ORR in this trial
was not different between the bevacizumab and the pla-
cebo arms, potentially curative surgery was performed
in 55 (9.6%) patients on bevacizumab vs. 38 (6.6%) on
placebo (p=0.061) in the per protocol population. PFS
was significantly increased in the bevacizumab group,
9.4 vs. 8.0 months in the placebo group (HR 0.83, 97.5%
CI 0.72 to 0.95; p=0.0023). However, OS was 21.3
months in the bevacizumab group and 19.9 months in
the placebo group (HR 0.89, 97.5% CI 0.76 to 1.03;
p=0.077) [34]. Several observational phase IIIb/IV trials(e.g., First BEAT, BriTE) confirmed the safety profile of
bevacizumab in first-line mCRC patients receiving a var-
iety of chemotherapy regimens, namely FOLFOX, XELOX,
FOLFIRI, or capecitabine [39,40].
Four drug regimens for mCRC
After the negative trials combining a chemo-doublet
with bevacizumab and EGFR antibodies, four drug regi-
mens focused on a chemo-triplet in combination with a
targeted drug [41,42]. Several chemo-triplet schedules
with 5FU/LV or capecitabine, irinotecan and oxaliplatin
were evaluated with the Italian FOLFOXIRI demonstrat-
ing the most efficacious and reliable data [37,43-46]. The
FOLFOXIRI regimen by Falcone et al. significantly
increased ORR (34 vs. 60%, p<0.0001), PFS (6.9 vs. 9.8
months, p=0.0006), and OS (16.7 vs. 22.6 months,
p=0.032) compared to FOLFIRI in a phase III trial with
244 patients. Furthermore, the FOLFOXIRI regimen
resulted in an increased R0 secondary resection rate (6%
vs. 15%, p=0.033, among all 244 patients; and 12 vs.
36%, p=0.017 among patients with CLM only) [37].
Administration of second line does not seem to be rele-
vantly impaired by first line FOLFOXIRI according to
recently presented data demonstrating feasibility and
efficacy of second line treatment with either oxaliplatin
or irinotecan based doublet (38%), rechallenge with
FOLFOXIRI (24%) or fluoropyrimidine with or without
mitomycin [47]. Retreatment with FOLFOXIRI was
associated with significantly prolonged survival.
Several single arm phase II trials with different 5FU/LV,
irinotecan and oxaliplatin schedules were performed in
combination with either bevacizumab or cetuximab
resulting in high ORR of 75-82% [48-53]. However,
in the absence of comparative data, toxicity profile
(especially grade 3/4 diarrhoea) seems to favour
bevacizumab-containing regimens (14-28%) compared
to 36-93% observed with cetuximab combinations
even after dose reduction of chemotherapy.
In a recently published single arm phase II trial, an
ORR of 77% in all patients and 80% in the liver-only
population (n=30) was achieved with the combination
of FOLFOXIRI and bevacizumab. R0 resections were
performed in 40% (n=12) of the liver-only population.
Disease control rate was 100%. PFS and OS were 13.1
and 30.9 months, respectively. Treatment was well tol-
erated with the major grade 3/4 toxicity being neutro-
penia in 49% of patients (compared to 50% with
FOLFOXIRI alone), which was well manageable with sec-
ondary G-CSF prophylaxis leading to only one case of fe-
brile neutropenia. Further G3/4 toxicities were diarrhoea
in 14%, hypertension in 11%, and asthenia as well as deep
vein thrombosis in 7% of patients [52]. Similar results
could be achieved in another 5FU/LV, irinotecan and oxa-
liplatin regimen (weekly alternating “Poker” schedule) with
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Both trials are multicentre, open labelled, prospective,
randomized phase II studies. The study protocols were
approved by the local ethics committees, and were also
subject to authorization by the competent authority
(BfArM for CHARTA and PEI for PERIMAX) as
mandatory by federal law. All participants have to pro-
vide written informed consent. The trials were assigned
the EudraCT numbers 2010-022162-27 for CHARTA
and 2010-023575-25 for PERIMAX and are registered at
ClinicalTrials.gov (CHARTA: NCT01321957, PERIMAX:
NCT01540435).
Study objectives and endpoints
The primary objective of the CHARTA study is to
evaluate the efficacy of FOLFOXIRI and bevacizumab
compared to FOLFOX and bevacizumab in patients
with initially unresectable metastatic colorectal cancer.
Secondary objectives are safety and tolerability of the
treatment, efficacy in terms of secondary resectability,
prognostic value of stratification into clinical groups,
and validity of allocation to these groups and the
exploratory question whether the addition of irinotecan
might be more effective in terms of response and sur-
vival in patient groups to be determined by angiogenic
marker profiles, potentially indicating different sensi-
tivity to bevacizumab. Primary endpoint is PFS rate at
9 months; secondary endpoints include PFS, OS, ORR
(according to RECIST v1.1), secondary resection rate,
toxicity (according to NCI-CTCAE v4.0) and quality
of life (according to EORTC QLQ-C30 and modules
CR29 and CIPN20) [55]. PFS is defined as time from
randomization to date of first observed progression or
death (without reintroduction).
The primary objective of the PERIMAX study is to
evaluate the efficacy of FOLFOX for 6 months post-
operatively compared to FOLFOXIRI and bevacizumab
for three months pre- and three months postoperatively
for primarily resectable liver metastases from colorectal
cancer. Secondary objectives are safety and tolerability
of the treatment as well as efficacy in terms of survival.
Primary endpoint is failure- free survival (FFS) rate at
18 months. Failure will be defined as macroscopically
incomplete resection (R2), local or distant recurrence or
death from any cause. Secondary endpoints are PFS,
FFS, OS, achievability of macroscopically complete re-
section (R0/1), ORR (according to RECIST v1.1) afterpreoperative treatment (arm B), toxicity (according to
NCI-CTCAE v 4.0), perioperative morbidity, quality
of life (according to EORTC QLQ-C30 and module
LMC21), and survival according to molecular or clinico-
pathological factors.
Patient selection
Patients with histologically confirmed diagnosis of
mCRC can be included in the CHARTA-PERIMAX
trials, independent of synchronous or metachronous me-
tastases, although in case of synchronous disease in the
PERIMAX trial the primary tumour needs to be asymp-
tomatic and clearly R0 resectable. Inclusion into the
PERIMAX trial is limited to patients with R0 resectable
CLM as judged by the treating physician and thus
excludes patients with extrahepatic disease. Measurable
disease according to RECIST, adequate ECOG-PS (≤2 in
CHARTA, although ECOG-PS 2, only if tumour related;
≤1 in PERIMAX), age≥18 (upper limit in the PERIMAX
at 75 years of age), prior adjuvant treatment completed
either at least 6 months before inclusion in the
CHARTA, or at least 12 months for oxaliplatin-based
treatment in the PERIMAX, are further selection cri-
teria. Prerequisite laboratory values for both trials are
absolute neutrophil counts ≥1.5 x 109/L, platelets ≥100
x109/L, haemoglobin ≥9 g/dl or 5.59 mmol/l, INR <1.5
and aPTT < 1.5 Upper Limit of Normal (ULN) for
patients not receiving therapeutic anticoagulation (use
of full dose anticoagulants is allowed as long as the
INR or aPTT is within therapeutic limits and the pa-
tient has been on a stable dose for anticoagulants for
at least two weeks at the time of registration), serum
transaminases (AST & ALT) ≤ 2.5 x ULN (in case of
liver metastases < 5 x ULN), total bilirubin ≤ 1.5 x
ULN, and creatinine ≤ 1.5 x ULN. Further selection cri-
teria are based on current standard criteria (e.g. no preg-
nancy or breast feeding, signed and dated consent form)
and the contraindications of the used agents (e.g. severe
thrombosis or bleeding, major surgery within 28 days,
chronic diarrhoea or significant peripheral neuropathy).
Treatment schedule
Treatment schedules for CHARTA and PERIMAX are
summarized in Figures 1 and 2, respectively. Patients
will randomly be assigned in a 1:1 ratio stratified for the
clinical groups one to three mentioned in Table 1 in the
CHARTA trial and for number of CLM ≤3 vs >3 and
Fong score <2 vs. ≥2 in the PERIMAX trial.
CHARTA trial
Induction chemotherapy with a modified FOLFOX with
oxaliplatin at a dose of 85 mg/m2 iv over two hours
(day 1), LV at a dose of 200 mg/m2 iv over two hours











Strata: clinical groups 
• unresectable liver and/or lung metastasis          
potentially resectable after treatment induced 
downsizing, comorbidities allowing surgery
• multiple metastasis, rapid progression, risk of rapid 
deterioration, unlikely to become resectable
• never resectable and no symptoms or risk of 
deterioration
Maintenance 
• until PD or toxicity 
• after secondary resection 
maximum of 12 months
Bevacizumab+5FU/LV or 
Capecitabine
Figure 1 overview CHARTA trial.
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iv over 30 to 90 min (day 1) with or without irinotecan
at a dose of 165 mg/m2 iv over one hour (day 1) in a bi-
weekly schedule will be administered followed by main-
tenance with either 5-FU/LV and bevacizumab (same
dosage and schedule as above) or capecitabine at a dose
of 1600 mg/m2 in two doses po day 1 to 14 and bevaci-
zumab at a dose of 7.5 mg/kg iv over 30 to 90 min (day 1)
every three weeks (choice of 5-FU or capecitabine is at the
discretion of the investigator). Treatment with FOLFOX
and bevacizumab +/− irinotecan will be administered until
progression, intolerable toxicity, and secondary resection
or for a maximum of 12 cycles (6 months). After 6 months
of treatment and/or no progression patients will continue
with a maintenance regimen with bevacizumab and a
fluoropyrimidine for up to 12 months in the absence of
progression or intolerable toxicity. Maximum treatment
duration is 18 months (6 months of FOLFOX and bevaci-
zumab +/− irinotecan followed by 12 months of mainten-
ance). In case of secondary resection (at any time point)
treatment should be resumed 4–8 weeks postoperatively
for a total of 6 months FOLFOX and bevacizumab +/−
irinotecan (pre- and postoperative treatment), followed
by maintenance treatment for total treatment duration
of up to 12 months in the absence of progression or in-
tolerable toxicity. Reintroduction of oxaliplatin +/− iri-




• CLM ≤3 vs. >3
• Fong score <2 vs. 2
R
Therapy-naive CRC 




Figure 2 overview PERIMAX trial.disease during maintenance or complete break after 18
months of treatment is at the investigators discretion.
PERIMAX trial
The same regimens as in the CHARTA trial will
be administered, although the postoperative treatment
in arm A is FOLFOX without bevacizumab. In arm A
FOLFOX will be administered for 12 cycles (6 months)
postoperatively starting 6 +/−2 weeks after surgery. In
the perioperative arm (B) FOLFOXIRI and bevacizumab
will be administered for 6 cycles (last cycle without bev-
acizumab) (3 months) preoperatively, followed by liver
surgery within 6+/−2 weeks after last treatment FOLFOX-
IRI (without bevacizumab), followed by 6 cycles (3 months)
6+/−2 weeks postoperatively. Bevacizumab should be
withheld for at least 5 weeks before conducting surgery.
The first cycle of FOLFOXIRI in both trials can be
administered with 75% of dosage, if no diarrhoea or
other significant toxicities ≥ grade 2 occurs, following
cycles should be administered in full dosage. Dose
reduction and escalation is at the discretion of the inves-
tigator. Preoperative dose modifications should be main-
tained for postoperative treatment in the PERIMAX
trial. If a patient was treated with full dose preopera-
tively, dose reduction to 75% for the first cycle and
subsequent escalation might be applied similar to pre-
operative treatment. Doses of drugs will be reduced inFOLFOX
6 monthsSurgery
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adequate recovery from toxicity.
Assessments/follow up
Tolerability will be evaluated at every visit including
physical examination, vital signs, clinical laboratory pro-
file, and adverse events, which will be graded according
to NCI-CTCAE v.4.0 and correlated to the administered
treatment or performed study procedure. Treatment
related Serious Adverse Events (SAE) considered pos-
sibly, probably or definitely related to treatment, will
be determined.
In both trials the investigator will assess tumour
response according to RECIST v1.1 and CEA (optional
CA 19–9). CT and/or MRI scans will be independently
reviewed e.g. for resectability (both trials) and allocation
to the clinical groups (CHARTA). In the CHARTA trial
imaging of all sites of disease will be performed at baseline
and every 4 cycles (8 weeks) thereafter for the first 6 months
(induction treatment) and afterwards every 3 months (dur-
ing and after maintenance) until progression.
Radiological imaging in the PERIMAX trial (CT-scan
of the chest, CT or MRI-scan of the abdomen) should
be done at baseline and/or preoperatively, postopera-
tively (prior to the start of postoperative treatment) and
afterwards every three months for two years and every
6 month thereafter in both arms. In the preoperatively
treated arm, an additional radiological imaging after the
3rd cycle (6 weeks) should be done to avoid clinically
complete response. In case of CEA elevation without
progressive disease defined by RECIST, further examina-
tions must be performed searching for local recurrence
or metastatic progression of disease. Diagnosis of recur-
rence could either be made by radiological imaging or
by positive cytology or biopsy. After progression,
patients will be followed every 3 months for disease sta-
tus, protracted toxicities, further treatment, and survival.
Quality of life will be assessed together with tumour
assessment using the EORTC QLQ-C30, and the mod-
ules CR29 and CIPN20 in the CHARTA and the module
LMC21 in the PERIMAX.
Formalin fixed and paraffin embedded (FFPE) tumour
tissue obtained at baseline (if available) and serum
obtained at baseline and before the 3rd and the 7th cycle
will be evaluated for KRAS and BRAF-status (FFPE) and
angiogenic markers (FFPE and serum) in the CHARTA
trial. In addition to KRAS and BRAF in PERIMAX
evaluation of pathohistological response rate and further
analyses are planned, thus either paraffin embedded or
preferably fresh frozen tissue of primary tumour and
hepatic metastases should be obtained in patients con-
senting. Furthermore, serum obtained at baseline, during
preoperative treatment, postoperatively and at follow up
will be evaluated for circulating tumour DNA.Statistical considerations and sample size estimation
CHARTA trial
First line therapy with FOLFOX and bevacizumab displays
a median PFS of 9,4 months [34], leading to a PFS Rate at
9 months (PFSR@9) of approximately 55%. The four-drug
combination treatment should produce a PFSR@9 of at
least 71.3%. The risk of estimating the four-drug combin-
ation treatment as active although the PFSR@9 is less than
71.3% should be 10%. The risk of rejecting the therapy
although the PFSR@9 is more than 71.3% should be 20%,
which leads to a power of 80%. The planned number of
patients to answer this question in a two-sided (continuity
corrected) Chi-square test will be 120 and with a dropout
rate of 4% the number to be included will be 125 patients
per arm. Analysis will be performed by logistic regression
to account for the stratification.
PERIMAX trial
Perioperative chemotherapy with 5-FU/LV with or
without oxaliplatin in a prognostic favourable group
of patients with up to 4 CLM led to a FFS rate at
18 months (FFSR@18) of 50-65% [22,25]. However, in the
trial by Portier et al.. solely patients after R0 resection
were included, whereas in the EORTC study 51% and
27% of patients had one or two CLM, respectively. In this
trial, patients with unlimited number of CLM, fulfilling
the local judgement for resectability will be included.
Therefore, FFSR@18 is expected to be 40% with current
treatment strategies (postoperative FOLFOX). The inves-
tigational treatment (perioperative FOLFOXIRI and beva-
cizumab) should produce a FFSR@18 of at least 60%, to
be regarded as promising for further evaluation and of
major clinical relevance. The trial should achieve 80%
power to detect differences between the treatments and
keeping the type I error level below 10% in a one-sided
(continuity corrected) Chi-square test. The planned num-
ber of patients to answer this question with a drop out
rate of about 14% will be 65 patients per arm. The trial
uses a randomized parallel arm phase II design.
Quality assurance/safety
Patient data are collected in a case report form at
the data centre of the clinical research organisation
(Koordinierungszentrum für Klinische Studien Halle).
Consistency checks will be performed on newly entered
forms and queries issued in case of inconsistencies. On-
site monitoring will be performed adapted according
to the site accrual. Data safety monitoring boards will
review the data from both trials on a regular basis.
Discussion
The CHARTA and PERIMAX trials are designed to
evaluate the benefits and limitations of a highly active
four-drug regimen in different treatment situations of
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an experimental treatment with FOLFOXIRI and bevaci-
zumab vs. what is considered a standard approach.
Perioperative treatment in resectable CLM, especially
its sequence (peri- vs. postoperative treatment) and
intensity, is still a matter of debate. The PERIMAX trial
design represents the agreement on a multidisciplinary
trial by surgical and medical oncologists in Germany
and reflects the ongoing discussion about timing of peri-
operative chemotherapy. In regard of the high recur-
rence rate after resection with curative intent and the
results of four drug combinations including bevacizumab
in mCRC, further intensification of the perioperative
treatment to improve patients’ prognosis by increasing
the rate of long-term survivors seems to be a feasible op-
tion. Despite the lack of data for FOLFOX for purely
postoperative treatment after resection of CLM, this
regimen was chosen in regard of the beneficial trend for
5FU/LV in this setting and the data obtained in stage III
disease with oxaliplatin [27,56,57]. Furthermore, this
treatment approach is widely used for patients receiving
upfront resection of CLM, and is considered a ‘current
standard’ for this patient group. However, the PERIMAX
trial has several variables (sequence and intensity) and is
therefore of an exploratory nature focusing on the effi-
cacy and feasibility of perioperative FOLFOXIRI and
bevacizumab in this setting. The randomized design was
chosen to collect data albeit limited by the low number
of patients on the comparative efficacy in terms of sur-
vival in order to reduce the bias that is associated with a
comparison to historical controls, which are only avail-
able for 5FU/LV in this setting [58]. Number of CLM
with a cut-off value of 3 was added to the widely
accepted stratification according to the Fong score.
Although already part of the Fong score, this cut off
value has recently demonstrated high prognostic value
[15]. The composite endpoint FFS was chosen to adapt
to the specific situation in this trial with half of the
patients being disease-free within the first months after
randomization, compared to the other half receiving
3 months of preoperative treatment. In order to ensure
comparability with available data, e.g. EORTC 40983
(PFS), and to gain information about tolerability and
QoL with the four-drug regimen secondary endpoints
include these parameters. Perioperative treatment was
limited to 6 months, as no conclusive data about pro-
longed treatment is currently available [30]. The trial also
offers the unique opportunity of collecting tissue from
liver metastases and primary tumours either untreated or
treated. Therefore, fresh frozen and paraffin embedded
tissue will be collected and stored for further analyses.
The CHARTA trial will evaluate the efficacy of a max-
imal intensive first line regimen compared to a standard
first line regimen in patients with unresectable metastaticCRC. The intensification of first line treatment is
believed to increase the rate of patients amenable for a
secondary curative approach and even if surgery might
not be an option this treatment approach could result in
improved long-term disease control. Especially for clin-
ical group 2 and 3, if amenable for intensive first line
treatment, disease control after induction chemotherapy
could result in long intervals of either low toxic mainten-
ance therapy or complete treatment discontinuation and
might thus be a reasonable long-term approach. Fur-
thermore, the magnitude and point in time of tumour
response has demonstrated significant impact on prog-
nosis, underlining the need for an intensive first line
regimen inducing early tumour shrinkage [59]. Eligible
patients will be stratified according to clinical groups
in order to balance the arms especially for potentially
secondary resectable patients. PFS-rate at 9 months was
chosen as primary endpoint to gain information about
the comparative efficacy in terms of a survival endpoint,
taking into account the inclusion of all metastatic and
not only potentially resectable patients. Treatment dur-
ation is limited to a maximum of 6 months FOLFOX
and bevacizumab +/− irinotecan, followed by up to 12
months of maintenance with fluoropyrimidine and beva-
cizumab. According to current clinical standard oxalipla-
tin should be discontinued at least after 6 months of
treatment due to significant cumulative side effects, par-
ticularly peripheral neuropathy. None of the available
trials with FOLFOXIRI with or without bevacizumab
continued treatment beyond 12 cycles (6 months), as
tolerability will be significantly impaired and achieve-
ment of secondary resectability with prolonged treatment
beyond 6 months seems unlikely [37,52]. In the CELIM
trial for example median time to resection or exploration
was 5.1 months, with a median number of 8 treatment
cycles until intervention [60]. Current data support
the use of maintenance treatment after first line chemo-
therapy, though the choice of regimen is not yet clear
[61-64]. However, results of ongoing trials (e.g. AIO 0207
and CAIRO3) might help clarifying this question and
potentially the choice of maintenance regimen as well
(biological +/− fluoropyrimidine. In regard of the higher
intensity of the four-drug combination not only in terms
of response but as well in terms of toxicity QoL evalu-
ation is performed during the trial.
With overall 380 previously untreated metastatic
CRC patients classified for resectability, stratified for
clinical grouping and randomized, the CHARTA and
PERIMAX trials will give further information about
the benefit and tolerability of FOLFOXIRI and bevaci-
zumab in these distinct disease settings.
Abbreviations
5-FU, 5-fluorouracil; 5-yOSR, 5 year overall survival rate; AE, Adverse event;
ALT, Alanin-aminotransferase; AST, Aspartat-aminotransferase; aPTT, Activated
Stein et al. BMC Cancer 2012, 12:356 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/356partial thromboplastin time; BfArM, Bundesinstitut für Arzneimittel und
Medizinprodukte; BRAF, V-raf murine sarcoma viral oncogene homolog B1;
CA 19–9, Carbohydrate antigen 19–9; CEA, Carcinoembryonic antigen;
CLM, Colorectal liver metastases; CT, Computed tomography; DFS, Disease
free survival; DNA, Deoxyribonucleic acid; ECOG-PS, Eastern cooperative
oncology group – performance status; EGFR, Epidermal growth factor
receptor; EORTC, European organisation for research and treatment of
cancer; EudraCT, European Clinical Trials Database; FFS, Failure free survival;
FFSR@18, Failure free survival rate at 18 months; FOLFIRI, 5-FU/LV and
irinotecan; FOLFOX, 5-FU/LV and oxaliplatin; FOLFOXIRI, 5-FU/LV, oxaliplatin
and irinotecan; G, Grade; G-CSF, Granulocyte colony-stimulating factor;
HR, Hazard ratio; IFL, 5FU bolus and irinotecan regimen; INR, International
Normalized Ratio; Iv, Intravenous; KRAS, Kirsten rat sarcoma viral oncogene
homolog; LV, Leucovorin; mCRC, Metastatic colorectal cancer; min, Minutes;
MRI, Magnetic resonance imaging; N, Number of patients; NCI-
CTCAE, National Cancer Institute common terminology criteria for adverse
events; ORR, Overall response rate; OS, Overall survival; P, P-value; PEI, Paul
Ehrlich Institut; PFS, Progression free survival; PFSR@9, Progression free
survival rate at 9 months; Po, Per os; RECIST, Response evaluation criteria in
solid tumours; SAE, Severe adverse event; QoL, Quality of life; QLQ, Quality of
life questionnaire; UICC, Union internationale contre le cancer; ULN, Upper
Limit of Normal; V, Version; Vs, Versus; XELOX, Capecitabine and oxaliplatin.
Competing interests
Both trials are funded by Roche. AS has received honoraria from Roche and
Merck KGaA. HJS has received research funding and honoraria from Roche.
H-JS and DA have received honoraria and research funding from Roche and
Merck KGaA and honoraria from Amgen. BH has received honoraria and
research funding from Amgen, Roche and Merck KGaA. AW, AK, GG, MR and
TE declare that there is no conflict of interest.
Authors’ contributions
AS and GG prepared the manuscript. HJS and H-JS are the coordinating
investigators for the two trials and participated in the preparation of
manuscript and study protocols. AS wrote both study protocols, GG
participated in the PERIMAX protocol. DA coordinates the translational part
of the CHARTA trial. AW performed the statistical analysis for both trials and
participated in drafting of the manuscript. MR coordinates both trials as
clinical research associate. TE, BH, SH, GI, AK participate in patient
recruitment in both trials. All authors read and approved the final
manuscript.
Author details
1University Cancer Center Hamburg, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany. 2Department of Surgery, University
Medical Center Regensburg, Regensburg, Germany. 3Department for
Oncology/Hematology, Martin-Luther-University Halle, Ernst-Grube-Str. 40,
06120 Halle/Saale, Germany. 4MedCenter Nordsachsen, Schkeuditz, Germany.
5Charité Centrum für Tumormedizin, Campus Virchow-Klinikum, Berlin,
Germany. 6Department for Gastroenterology, Academic Teaching Hospital,
Celle, Germany. 7Department of Hematology/Oncology, Comprehensive
Cancer Center University of Freiburg, Freiburg, Germany. 8Department of
Surgery, University Hospital of Tübingen, Tübingen, Germany.
9Koordinierungszentrum Klinische Studien Halle, Martin-Luther-University,
Halle, Germany.
Received: 11 April 2012 Accepted: 17 July 2012
Published: 16 August 2012
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010,
127(12):2893–2917.
3. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM,
Kranse R, Verhoef C: Trends in incidence, treatment and survival of
patients with stage IV colorectal cancer: a population-based series.
Colorectal Dis 2012, 14:56–61.
4. Mantke R, Schmidt U, Wolff S, Kube R, Lippert H: Incidence of synchronous
liver metastases in patients with colorectal cancer in relationship toclinico-pathologic characteristics. Results of a German prospective
multicentre observational study. Eur J Surg Oncol 2012, 38:259–265.
5. Schmoll HJ, Sargent D: Single agent fluorouracil for first-line treatment of
advanced colorectal cancer as standard? Lancet 2007, 370:105–107.
6. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F,
De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, et al: Molecular markers
and biological targeted therapies in metastatic colorectal cancer: expert
opinion and recommendations derived from the 11th ESMO/World
Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010,
21(Suppl 6):vi1–10.
7. Schmiegel W, Pox C, Arnold D, Porschen R, Rodel C, Reinacher-Schick A:
Colorectal carcinoma: the management of polyps, (neo)adjuvant
therapy, and the treatment of metastases. Dtsch Arztebl Int 2009,
106:843–848.
8. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A,
Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in metastatic
colorectal cancer is associated with adoption of hepatic resection and
improved chemotherapy. J Clin Oncol 2009, 27:3677–3683.
9. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B,
Poston G: Surgical management and outcomes of colorectal cancer liver
metastases. Br J Surg 2010, 97:1110–1118.
10. Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, Neumann U,
Rudolph B, Neuhaus P: Extended resections of liver metastases from
colorectal cancer. World J Surg 2007, 31:511–521.
11. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S: Survival after
hepatic resection for colorectal metastases: a 10-year experience.
Ann Surg Oncol 2006, 13:668–676.
12. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M,
Kemeny N, Brennan MF, Blumgart LH, D’Angelica M: Actual 10-year survival
after resection of colorectal liver metastases defines cure.
J Clin Oncol 2007, 25:4575–4580.
13. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal
liver metastases. World J Surg 1995, 19:59–71.
14. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for
predicting recurrence after hepatic resection for metastatic colorectal
cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309–318.
discussion 318–321.
15. Adam R, Barroso E: Impact of the type and modalities of preoperative
chemotherapy on the outcome of liver resection for colorectal
metastases. J Clin Oncol 2011, 29:abstr 3519.
16. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA,
Aldrighetti L, Capussotti L, Pawlik TM: Rates and patterns of recurrence
following curative intent surgery for colorectal liver metastasis: an
international multi-institutional analysis of 1669 patients. Ann Surg 2009,
250:440–448.
17. Nagashima I, Takada T, Nagawa H, Muto T, Okinaga K: Proposal of a new
and simple staging system of colorectal liver metastasis.
World J Gastroenterol 2006, 12:6961–6965.
18. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF,
Nordlinger B, Adam R, Gruenberger T, Choti MA, et al: Urgent need for a
new staging system in advanced colorectal cancer. J Clin Oncol 2008,
26:4828–4833.
19. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G,
Ychou M, Rougier P: Towards a pan-European consensus on the
treatment of patients with colorectal liver metastases. Eur J Cancer 2006,
42:2212–2221.
20. Yamaguchi T, Mori T, Takahashi K, Matsumoto H, Miyamoto H, Kato T:
A new classification system for liver metastases from colorectal cancer in
Japanese multicenter analysis. Hepatogastroenterology 2008, 55:173–178.
21. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G,
Rougier P, Sobrero A, Ychou M: Combination of surgery and
chemotherapy and the role of targeted agents in the treatment of
patients with colorectal liver metastases: recommendations from an
expert panel. Ann Oncol 2009, 20:985–992.
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P,
Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al: Perioperative
chemotherapy with FOLFOX4 and surgery versus surgery alone for
resectable liver metastases from colorectal cancer (EORTC Intergroup
trial 40983): a randomised controlled trial. Lancet 2008, 371:1007–1016.
23. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T,
Mudan S, Brown G, Khan A, Wotherspoon A, et al: A multicentre study of
Stein et al. BMC Cancer 2012, 12:356 Page 9 of 10
http://www.biomedcentral.com/1471-2407/12/356capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of
patients with poor-risk colorectal liver-only metastases not selected for
upfront resection. Ann Oncol 2011, 22:2042–2048.
24. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F,
Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as
neoadjuvant therapy for patients with potentially curable metastatic
colorectal cancer. J Clin Oncol 2008, 26:1830–1835.
25. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P,
Guimbaud R, Nordlinger B, et al: Multicenter randomized trial of adjuvant
fluorouracil and folinic acid compared with surgery alone after resection of
colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol
2006, 24:4976–4982.
26. Langer B, Bleiberg H, Labianca R, et al: Fluorouracil (FU) plus l-leucovorin
(l-LV) versus observation after potentially curative resection of liver or
lung metastases from colorectal cancer (CRC): results of the ENG
(EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002,
21(abstr 592):2002.
27. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V,
Elias D, O’Callaghan C, et al: Adjuvant chemotherapy after potentially
curative resection of metastases from colorectal cancer: a pooled
analysis of two randomized trials. J Clin Oncol 2008, 26:4906–4911.
28. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C,
Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A:
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic
acid with FOLFIRI in patients following complete resection of liver
metastases from colorectal cancer. Ann Oncol 2009, 20:1964–1970.
29. Andre T, Van Cutsem E: A multinational, randomized phase III study of
bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as
adjuvant treatment for colon cancer (CC): Subgroup analyses from the
AVANT trial. J Clin Oncol 2011, 29:abstr 3509.
30. Voest EE, Snoeren N: A randomized two-arm phase III study to investigate
bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX)
versus CAPOX alone in post radical resection of patients with liver
metastases of colorectal cancer. J Clin Oncol 2011, 29:abstr 3565.
31. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH,
Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, et al: Phase III trial
assessing bevacizumab in stages II and III carcinoma of the colon: results
of NSABP protocol C-08. J Clin Oncol 2011, 29:11–16.
32. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y,
Bodoky G, Cunningham D, Jassem J, et al: Randomized, phase III trial of
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin
(FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: the PRIME study.
J Clin Oncol 2010, 28:4697–4705.
33. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S,
Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al: Cetuximab Plus
Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for
Metastatic Colorectal Cancer: Updated Analysis of Overall Survival
According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 2011,
29:2011–2019.
34. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with
oxaliplatin-based chemotherapy as first-line therapy in metastatic
colorectal cancer: a randomized phase III study. J Clin Oncol 2008,
26:2013–2019.
35. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH,
Idziaszczyk S, Harris R, Fisher D, Kenny SL, et al: Addition of cetuximab to
oxaliplatin-based first-line combination chemotherapy for treatment of
advanced colorectal cancer: results of the randomised phase 3 MRC
COIN trial. Lancet 2011, 377:2103–2114.
36. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A,
Celik I, Schlichting M, Koralewski P: Efficacy according to biomarker status
of cetuximab plus FOLFOX-4 as first-line treatment for metastatic
colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535–1546.
37. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L,
Benedetti G, Evangelista W, Fanchini L, et al: Phase III trial of infusional
fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)
compared with infusional fluorouracil, leucovorin, and irinotecan
(FOLFIRI) as first-line treatment for metastatic colorectal cancer: the
Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670–1676.38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med 2004, 350:2335–2342.
39. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M,
Mazier MA, Canon JL, Georgoulias V, Peeters M, et al: Safety and efficacy of
first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and
fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann
Oncol 2009, 20:1842–1847.
40. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff
M: Bevacizumab beyond first progression is associated with prolonged
overall survival in metastatic colorectal cancer: results from a large
observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326–5334.
41. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall
J, Cohn A, McCollum D, Stella P, et al: A randomized phase IIIB trial of
chemotherapy, bevacizumab, and panitumumab compared with
chemotherapy and bevacizumab alone for metastatic colorectal cancer.
J Clin Oncol 2009, 27:672–680.
42. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG,
Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al: Chemotherapy,
bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J
Med 2009, 360:563–572.
43. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M,
Bajetta R, Colombo A, Pusceddu S: Capecitabine plus oxaliplatin and
irinotecan regimen every other week: a phase I/II study in first-line
treatment of metastatic colorectal cancer. Ann Oncol 2007, 18:1810–1816.
44. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR,
Rivoire M, Quenet F, Portier G, Nordlinger B: Tritherapy with fluorouracil/
leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in
colorectal cancer patients with non-resectable liver metastases. Cancer
Chemother Pharmacol 2008, 62:195–201.
45. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A,
Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, et al: FOLFOXIRI (folinic
acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,
5-fluorouracil and irinotecan) as first-line treatment in metastatic
colorectal cancer (MCC): a multicentre randomised phase III trial from
the Hellenic Oncology Research Group (HORG). Br J Cancer 2006,
94:798–805.
46. Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A,
Ramirez N, Bitarte N, Chopitea A, Gacia-Foncillas J: Oxaliplatin, irinotecan
and capecitabine as first-line therapy in metastatic colorectal cancer
(mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer
2010, 102:987–994.
47. Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L,
Cremolini C, Cupini S, Cortesi E, et al: Outcome of Second-Line Treatment
After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen.
Clin Colorectal Cancer 2012, 11:71–76.
48. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E,
Portales F, Bibeau F, Crapez-Lopez E, et al: Cetuximab Plus FOLFIRINOX
(ERBIRINOX) as first-line treatment for unresectable metastatic colorectal
cancer: a phase II trial. Oncologist 2011, 16(11):1557–1564.
49. Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F,
Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E: “Poker”
association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab
and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal
cancer: a phase II study. BMC Cancer 2010, 10:567.
50. Trarbach T, Schuette J: Dose escalating study of 5-FU/folinic acid (FA)/
oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy
of patients with metastatic colorectal cancer. J Clin Oncol 2009,
27:abstr e15025.
51. Ychou M, Desseigne F: Preliminary results of a multicentre phase II trial
evaluating cetuximab in combination with FOLFIRINOX (LV5FU +
Irinotecan + Oxaliplatin) as first line treatment of metastatic colorectal
cancer (mCRC) patients. Gastrointestinal Cancers Symposium 2009, 2009
((Abstract-No: 295):abstr. 450.
52. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A,
Del Monte F, Cortesi E, Amoroso D, et al: Bevacizumab with FOLFOXIRI
(irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment
for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010,
11:845–852.
Stein et al. BMC Cancer 2012, 12:356 Page 10 of 10
http://www.biomedcentral.com/1471-2407/12/35653. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C,
Vennarecci G, Mottolese M, Sperduti I, Cognetti F: Cetuximab plus
chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as
neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Br J Cancer 2010, 103:1542–1547.
54. Falcone A, Loupakis F: FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI
plus BV as first-line treatment of metastatic colorectal cancer (MCRC):
Preliminary safety results of the phase III randomized TRIBE study by the
Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 2010, 28:abstr 3543.
55. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer 2009, 45:228–247.
56. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A,
Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival
with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in
stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009,
27:3109–3116.
57. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E,
Hill M, Gilberg F, Rittweger K, Schmoll HJ: Capecitabine Plus Oxaliplatin
Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for
Stage III Colon Cancer. J Clin Oncol 2011, 29:1465–1471.
58. Ratain MJ, Sargent DJ: Optimising the design of phase II oncology trials:
the importance of randomisation. Eur J Cancer 2009, 45:275–280.
59. Piessevaux H, Schlichting M: Early tumor shrinkage for the prediction of
efficacy of cetuximab in metastatic colorectal cancer: analysis from the
CRYSTAL study. Ann Oncol 2010, 21:abstr. 596.
60. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT,
Lang H, Frilling A, Stoehlmacher J, Weitz J, et al: Tumour response and
secondary resectability of colorectal liver metastases following
neoadjuvant chemotherapy with cetuximab: the CELIM randomised
phase 2 trial. Lancet Oncol 2010, 11:38–47.
61. Wasan H, Adams RA: Intermittent chemotherapy (CT) plus continuous or
intermittent cetuximab (C) in the first-line treatment of advanced
colorectal cancer (aCRC): Results of the two-arm phase II randomized
MRC COIN-b trial. J Clin Oncol 2012, 30:abstr 536.
62. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL,
Kay E, Hodgkinson E, Pope M, et al: Intermittent versus continuous
oxaliplatin and fluoropyrimidine combination chemotherapy for first-line
treatment of advanced colorectal cancer: results of the randomised
phase 3 MRC COIN trial. Lancet Oncol 2011, 12:642–653.
63. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T,
Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, et al: Can
chemotherapy be discontinued in unresectable metastatic colorectal
cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009, 27:5727–5733.
64. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M,
Rivera F, Safont MJ, Martinez de Prado P, Gallen M, et al: First-Line XELOX
Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent
Bevacizumab as Maintenance Therapy in Patients with Metastatic
Colorectal Cancer: The Phase III MACRO TTD Study. Oncologist 2012,
17:15–25.
doi:10.1186/1471-2407-12-356
Cite this article as: Stein et al.: Treatment with bevacizumab and
FOLFOXIRI in patients with advanced colorectal cancer: presentation of
two novel trials (CHARTA and PERIMAX) and review of the literature.
BMC Cancer 2012 12:356.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
